These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 5285940)

  • 1. Persistence of antibody after subcutaneous vaccination with Wistar RA27/3 rubella vaccine.
    Hillary IB
    J Hyg (Lond); 1971 Sep; 69(3):369-72. PubMed ID: 5285940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination of adults with Wistar RA 27/3 rubella vaccine.
    Freestone DS; Prydie J; Smith SG; Laurence G
    J Hyg (Lond); 1971 Sep; 69(3):471-7. PubMed ID: 5285946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunisation of schoolchildren with rubella (RA27-3) vaccine. Intranasal and subcutaneous administration.
    Ingalls TH; Plotkin SA; Philbrook FR; Thompson RF
    Lancet; 1970 Jan; 1(7638):99-101. PubMed ID: 4188770
    [No Abstract]   [Full Text] [Related]  

  • 4. Rubella in Orkney: seroepidemiology and vaccination.
    Moffat MA; Heywood SN; Laughton E; Gould JJ; Freestone DS
    J Hyg (Lond); 1977 Jun; 78(3):419-27. PubMed ID: 266542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Specific immunoglobulin responses in serum and nasal secretions after the administration of attenuated rubella vaccine.
    Cradock-Watson JE; Macdonald H; Ridehalgh MK; Bourne MS; Vandervelde EM
    J Hyg (Lond); 1974 Aug; 73(1):127-41. PubMed ID: 4608331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous and intranasal administration of RA 27-3 rubella vaccine. Alone and in conjunction with live attenuated measles vaccine.
    Saidi S; Naficy K
    Am J Dis Child; 1969 Aug; 118(2):209-12. PubMed ID: 5794816
    [No Abstract]   [Full Text] [Related]  

  • 7. Vaccination with RA 27-3 rubella vaccine.
    Buser F; Nicolas A; L'Etoile M
    Am J Dis Child; 1971 Jul; 122(1):53-6. PubMed ID: 5567406
    [No Abstract]   [Full Text] [Related]  

  • 8. Antibody response in serum and nasopharynx after naturally acquired and vaccine-induced infection with rubella virus.
    Ogra PL; Kerr-Grant D; Umana G; Dzierba J; Weintraub D
    N Engl J Med; 1971 Dec; 285(24):1333-9. PubMed ID: 4107718
    [No Abstract]   [Full Text] [Related]  

  • 9. Persistence of antibody induced by rubella vaccine (Wistar RA 27/3 strain) after six years.
    Hillary IB; Freestone DS
    J Hyg (Lond); 1975 Dec; 75(3):407-11. PubMed ID: 1059708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on the reactogenicity and immunogenicity of the BRD-2 and RA27/3 live attenuated rubella vaccines.
    Wang SS; Han YR; Su WN; Chen J; Zhao K
    Vaccine; 1984 Dec; 2(4):277-80. PubMed ID: 6531968
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artificial challenge studies in rubella. Utilization of RA 27-3 rubella vaccines, rubella naturally acquired seropositives, and rubella susceptible children.
    Naficy K; Nategh R; Ahangary S; Mohsenin H
    Am J Dis Child; 1970 Dec; 120(6):520-3. PubMed ID: 5481902
    [No Abstract]   [Full Text] [Related]  

  • 12. Antibody response in school children to live rubella vaccine (Cendehill strain).
    Iwakata S; Elkerton LE; Rhodes AJ; Bull JA; Labzoffsky NA
    Can Med Assoc J; 1972 May; 106(9):980-2. PubMed ID: 4554732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies with rubella vaccine (RA 27-3) using the subcutaneous and intranasal routes.
    Moffat MA; Gould JJ; Forbes FA; Freestone DS; Macdonald A
    Scott Med J; 1972 Apr; 17(4):140-2. PubMed ID: 4554067
    [No Abstract]   [Full Text] [Related]  

  • 14. Combined live rubella-mumps virus vaccine. Findings in clinical-laboratory studies.
    Weibel RE; Stokes J; Villarejos VM; Arguedas JA; Buynak EB; Hilleman MR
    JAMA; 1971 May; 216(6):983-6. PubMed ID: 5108387
    [No Abstract]   [Full Text] [Related]  

  • 15. Loss of rubella hemagglutination inhibition antibody in congenital rubella. Failure of seronegative children with congenital rubella to respond to HPV-77 rubella vaccine.
    Cooper LZ; Florman AL; Ziring PR; Krugman S
    Am J Dis Child; 1971 Nov; 122(5):397-403. PubMed ID: 5129528
    [No Abstract]   [Full Text] [Related]  

  • 16. Attenuated rubella vaccine (HPV-77): evaluation in a large controlled trial.
    Lipman RP; Bethel MB; Wooten JH; Levine RH; Pagano JS
    Am J Public Health; 1971 Jul; 61(7):1392-402. PubMed ID: 4935166
    [No Abstract]   [Full Text] [Related]  

  • 17. Persistence of vaccine-induced immune responses to rubella: comparison with natural infection.
    Horstmann DM; Schluederberg A; Emmons JE; Evans BK; Randolph MF; Andiman WA
    Rev Infect Dis; 1985; 7 Suppl 1():S80-5. PubMed ID: 4001740
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intranasal versus subcutaneous rubella vaccination in schoolgirls.
    Midulla M; Assensio AM; Balducci L; Vanni O; Msstropasqua S
    Dev Biol Stand; 1976; 33():241-8. PubMed ID: 955270
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody titres in women six to eight years after the administration of RA2713 and Cendehill rubella vaccines.
    Macdonald H; Tobin JO; Cradock-Watson JE; Lomax J
    J Hyg (Lond); 1978 Jun; 80(3):337-47. PubMed ID: 649946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Persistence of antibody titers after vaccination with rubella virus vaccine ("Cendehill" strain).
    Peetermans J; du Pan RM; Huygelen C
    Dev Biol Stand; 1979; 43():361-5. PubMed ID: 520683
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.